DRUG · Unmapped registry intervention
PF-05082566
Find medicine records ·
Find other trials using this name
Clinical trial
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307267
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
rituximab
Normalized identity: rituximabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
PF-05082566
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lymphoma, Follicularcandidate · MONDO: follicular lymphoma
Lymphoma, Large B-Cell, Diffuseunresolved
Carcinoma, Renal Cellcandidate · MONDO: renal cell carcinoma
Malignant Melanomaverified · MONDO: melanoma
Interventions
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
St LouisMissouri, United States5AtlantaGeorgia, United States5Los AngelesCalifornia, United States4La JollaCalifornia, United States3BostonMassachusetts, United States2SeattleWashington, United States2Washington D.C.District of Columbia, United States2Palo AltoCalifornia, United States2New YorkNew York, United States1HoustonTexas, United States1San AntonioTexas, United States1San DiegoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01307267 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.